MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway

Resistance to doxorubicin (DOX) is the most common clinical problem in breast cancer therapy, and the underlying molecular mechanism remains to be investigated. MicroRNAs (miRNAs) exhibit important regulatory functions in various malignant tumors including breast cancer. The aim of the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Hong, Xu, Ling-yun, Qian, Qi, Zhu, Qiu-wei, Chen, Wei-xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629945/
https://www.ncbi.nlm.nih.gov/pubmed/31273056
http://dx.doi.org/10.1042/BSR20190650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629945/
https://www.ncbi.nlm.nih.gov/pubmed/31273056
http://dx.doi.org/10.1042/BSR20190650

Ejemplares similares